The benefits of CUROSURF® (poractant alfa) work together to deliver fast RDS success in conventionally treated infants1-4
CUROSURF offers proven success with an early rescue INSURE (Intubate—Surfactant—Rapid Extubation) strategy in cases of CPAP failure5-8
The benefits of CUROSURF may help you succeed in the reduction of surfactant utilization in your NICU3,5,6,9-13
CUROSURF—the #1 used surfactant in the US and worldwide —continues to keep pace with today's clinical practice14,15
*It is important to note that the INSURE strategy may not be appropriate for all infants. Infants with RDS may vary markedly in the severity of respiratory disease, maturity, and presence of other complications, and thus it is necessary to individualize patient care.
Meet with your Chiesi Sales Representative to learn more about CUROSURF.
*Required fields
Watch this informative overview video now.
Visit the CUROSURF YouTube page for more videos
Important Safety Information See More
CUROSURF® (poractant alfa) is intended for intratracheal use only. The administration of exogenous surfactants, including CUROSURF, can rapidly affect oxygenation and lung compliance. Therefore, infants receiving CUROSURF should receive frequent clinical and laboratory assessments so that oxygen and ventilatory support can be modified to respond to respiratory changes.
CUROSURF should only be administered by those trained and experienced in the care, resuscitation, and stabilization of preterm infants.
Transient adverse reactions associated with administration of CUROSURF include bradycardia, hypotension, endotracheal tube blockage, and oxygen desaturation. These events require stopping CUROSURF administration and taking appropriate measures to alleviate the condition. After the patient is stable, dosing may proceed with appropriate monitoring.
Pulmonary hemorrhage, a known complication of premature birth and very low birth-weight, has been reported with CUROSURF. The rates of common complications of prematurity observed in a multicenter single-dose study that enrolled infants 700–2000 g birth weight with RDS requiring mechanical ventilation and FiO2 ≥ 0.60 are as follows for CUROSURF 2.5 mL/kg (200 mg/kg) (n=78) and control (n=66; no surfactant) respectively: acquired pneumonia (17% vs. 21%), acquired septicemia (14% vs. 18%), bronchopulmonary dysplasia (18% vs. 22%), intracranial hemorrhage (51% vs. 64%), patent ductus arteriosus (60% vs. 48%), pneumothorax (21% vs. 36%) and pulmonary interstitial emphysema (21% vs. 38%).
Indication
CUROSURF® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS.
The information on this site is only intended for US Healthcare Professionals
![CUROSURF® (poractant alfa) Intratracheal Suspension is available in sterile, ready-to-use rubber-stoppered clear glass vials containing 1.5 mL [120 mg surfactant (extract)] or 3.0 mL [240 mg surfactant (extract)] of suspension. One vial per container.](/wp-content/themes/curosurf/assets/img/pills.png "CUROSURF Vials")